In the study of pulmonary fibrosis, it was found that the Axl‐targeting inhibitor R428 can effectively inhibit the proliferation and migration of pulmonary fibroblasts in patients with IPF, as well as inhibit pulmonary fibrosis in humanised SCID/Bg mice [16], suggesting that targeting Axl and its downstream signalling pathways may be a new therapeutic strategy in the fibrosis stage. Here, AXL is linked to idiopathic pulmonary fibrosis.